Vigil Neuroscience Q4 2023 net loss $22.2M; positive Phase 2 interim data for iluzanebart; cash runway extended

Vigil Neuroscience, Inc.

Q4 2023 net loss from operations $22.2M (vs $18.5M Q4 2022); full year net loss $82.6M (vs $68.3M 2022).
Cash, cash equivalents, and marketable securities $117.9M at Dec 31, 2023; cash runway extended into H2 2025.
Phase 2 IGNITE trial for iluzanebart in ALSP: positive interim data showing target engagement; enrollment completed with 20 patients; next data readout Q3 2024.
VG-3927 Phase 1 trial ongoing; interim data planned mid-2024; FDA partial clinical hold on maximum exposure limit, no expected delay.
Appointed Petra Kaufmann, M.D., as Chief Medical Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vigil Neuroscience, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

Vigil Neuroscience, Inc . (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-077088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.